Investigation of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Oral Doses of 75 mg Molidustat in Male and Female Subjects With Renal Impairment Requiring Hemo- or Peritoneal Dialysis Compared to Age- and Weight-matched Healthy Subjects in a Single-center, Non-controlled, Non-blinded Study With Group Stratification
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2016
At a glance
- Drugs Molidustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors Bayer
- 07 Jun 2017 Biomarkers information updated
- 14 Jun 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2020.